IRF2BP1 Antibody / Interferon regulatory factor 2-binding protein 1, 100 ug

IRF2BP1 antibody detects Interferon regulatory factor 2-binding protein 1, a transcriptional corepressor that modulates interferon signaling and immune gene expression. Encoded by the IRF2BP1 gene on chromosome 19q13.11, this protein functions as a transcriptional regulator by binding and repressing the activity of interferon regulatory factor 2 (IRF2). IRF2BP1 contains a C-terminal zinc finger domain that mediates DNA and protein interactions, as well as an N-terminal coiled-coil region that enables homo- and heterodimerization. It acts as a transcriptional corepressor by recruiting histone deacetylases and other chromatin-modifying enzymes to interferon-stimulated gene promoters.

IRF2BP1 plays an essential role in maintaining immune homeostasis and regulating the magnitude of antiviral and inflammatory responses. By modulating IRF2 and IRF1 target genes, it fine-tunes the balance between transcriptional activation and repression in interferon signaling pathways. IRF2BP1 also participates in the negative regulation of p53 and NF-?B target genes, thereby linking interferon signaling to cell survival and immune control. Its activity is regulated through post-translational modifications such as phosphorylation and SUMOylation, which alter subcellular localization and cofactor binding.

The IRF2BP1 antibody is widely used in immunology, virology, and transcriptional regulation studies to detect IRF2BP1 expression and nuclear localization. Western blot analysis typically identifies a 58 kilodalton band, and immunofluorescence reveals nuclear and perinuclear distribution patterns consistent with its function as a transcriptional repressor. This antibody enables researchers to examine the interplay between interferon signaling and chromatin regulation, as well as transcriptional repression during immune activation.

Dysregulation of IRF2BP1 expression has been associated with aberrant immune responses, chronic inflammation, and oncogenesis. It acts as a checkpoint that restrains excessive interferon responses, preventing autoimmunity. NSJ Bioreagents provides the IRF2BP1 antibody validated for western blotting, immunofluorescence, and immunohistochemistry, supporting high-quality detection of this transcriptional regulator in both normal and disease contexts.